Device company RxPack has joined the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) as an associate member, the company said. RxPack is a joint venture between Lindal Group and Coster Group that was formed in 2021 to distribute metered dose inhaler and nasal spray devices as well as Coster’s aerosol filling equipment.
RxPack CEO Massimo Carrara commented, “RxPack is growing its leadership and recognition in the world of pMDIs. Associate membership in IPAC-RS is timely and will facilitate our exposure of key trends and engagement on relevant global development and regulatory matters.”
Head of R&D Alberto Colombo added, “Being part of IPAC-RS is a great opportunity for us to share cross-industry knowledge that allows us to better support our pharmaceutical partners. Engaging in IPAC-RS will assist us as we maintain a dedicated focus on patients in this time of transition to green propellants for pMDI products.” This year’s RDD meeting included a number of discussions regarding the need for industry-wide participation in the transition to lower-GWP propellants such as HFA 152a and HFO1234ze.
Associate membership in IPAC-RS is available to device and device component companies; companies that provide development and/or manufacturing services for OINDPs; and smaller pharma companies that make and market OINDPs. Other companies that have joined IPAC-RS as associate members over the past few years include Nemera, Copley Scientific, and Proveris Scientific. CDMO Lonza recently joined IPAC-RS as a full member.
Read the RxPack press release.
